Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2013 Nov 12;8(11):e81275. doi: 10.1371/journal.pone.0081275. eCollection 2013.

Bioorthogonal small molecule imaging agents allow single-cell imaging of MET.

Author information

1
Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.

Abstract

The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that has emerged as an important cancer target. Consequently, a number of different inhibitors varying in specificity are currently in clinical development. However, to date, it has been difficult to visualize MET expression, intracellular drug distribution and small molecule MET inhibition. Using a bioorthogonal approach, we have developed two companion imaging drugs based on both mono- and polypharmacological MET inhibitors. We show exquisite drug and target co-localization that can be visualized at single-cell resolution. The developed agents may be useful chemical biology tools to investigate single-cell pharmacokinetics and pharmacodynamics of MET inhibitors.

PMID:
24265843
PMCID:
PMC3827223
DOI:
10.1371/journal.pone.0081275
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center